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Abstract
Objective:  We  aimed  to  describe  sociodemographic,  comorbidities,  co-medication  and  risk of
thromboembolic  events  and  bleeding  in  patients  with  NVAF  initiating  oral  anticoagulants  (OAC)
for stroke  prevention,  and to  estimate  adherence  and  persistence  to  OAC.
Setting:  Primary  Health  Care  (PHC)  in the Catalan  Health  Institute  (ICS),  Catalunya,  Spain.
Participants:  All  NVAF  adult  patients  initiating  OAC  for  stroke  prevention  in August
2013--December  2015.
Methods:  Population-based  cohort  study.  Persistence  was  measured  in  patients  initiating  OAC
in August  2013--December  2014.
Data source:  SIDIAP,  which  captures  electronic  health  records  from  PHC  in the  (ICS),  covering
approximately  5.8  million  people.
Results:  51,690  NVAF  patients  initiated  OAC;  47,197  (91.3%)  were  naive  to  OAC  and  32,404
(62.7%) initiated  acenocoumarol.  Mean  age  was  72.8  years  (SD  12.3)  and  49.4%  were  women.
Platelet-aggregation  inhibitors  were  taken  by  9105  (17.6%)  of  the patients.  Persistence  and
adherence were  estimated  up  to  the  end  of  follow-up.  For  22,075  patients,  persistence  was
higher among  the  non-naive  patients  [n  = 258  (61.7%)]  than  among  the  naive  [n  = 11,502  (53.1%)].
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Adherence  was  estimated  for  patients  initiating  DOAC  and  it  was  similar  in  naive  and  non-naive
patients.  Among  the  naive  to  DOAC  treatment,  those  starting  rivaroxaban  showed  a  highest
proportion  [(n =  360 (80.1%)]  of  good  adherence  at  implementation  (MPR  > 80%)  while  patients
starting  dabigatran  were  less  adherent  [n  = 203  (47.8%)].
Conclusions:  Acenocoumarol  was  the  most  frequently  prescribed  OAC  as  first  therapy  in NVAF
patients.  Non-naive  to  DOAC  showed  better  persistence  than  naive.  Rivaroxaban  showed  higher
proportion  of  adherent  patients  during  the  implementation  phase  than  apixaban  and  dabigatran
the lowest.
©  2020  The  Authors.  Published  by  Elsevier  España,  S.L.U.  This  is an  open  access  article  under
the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Uso  y adherencia  a los  anticoagulantes  orales  en  Atención  Primaria  en  Cataluña,
España:  estudio  de cohortes  con  datos  procedentes  de registros  electrónicos  de  salud
Resumen
Objetivo:  Describir  datos  sociodemográficos,  comorbilidades,  comedicaciones  y  riesgo  de even-
tos tromboembólicos  y  hemorrágicos  de los  pacientes  con  fibrilación  auricular  no  valvular  (FANV)
que inician  tratamiento  anticoagulante  por  vía  oral  (TAO)  para  prevención  del  ictus.  Estimar
adherencia y  persistencia  al  TAO.
Emplazamiento:  Atención  primaria  (AP)  del  Instituto  Catalán  de Salud  (ICS),  Cataluña,  España.
Participantes:  Adultos  con  FANV  que  inician  TAO  para  prevención  de  ictus  entre  agosto  del  2013
y diciembre  del  2015.
Métodos:  Estudio  de  cohortes  de base  poblacional.  Adherencia  y  persistencia  se  midieron  en
pacientes  que  iniciaban  TAO  entre  agosto  del  2013  y  diciembre  del  2014.
Fuente  de  datos:  SIDIAP,  base  de datos  procedentes  de  registros  electrónicos  de  AP  del  ICS,  que
cubre aproximadamente  una población  de 5,8  millones  de personas.
Resultados:  Cincuenta  y  un  mil  seiscientos  noventa  pacientes  con  FANV  iniciaron  TAO,
47.197 (91,3%)  eran  naïve  al  TAO  y  32.404  (62,7%)  iniciaron  acenocumarol.  Su  edad  media  era
72,8 años  (DE  12,3)  y  el 49,4%  eran  mujeres;  90105  (17,6%)  recibían  tratamiento  antiagregante
plaquetario.  Persistencia  y  adherencia  se  estimaron  hasta  el final  del seguimiento.  La  persis-
tencia a  anticoagulantes  orales  directos  (ACOD)  fue  mayor  en  no naïve  que  en  naïve  (61,7%  vs.
53,1%).  La  adherencia  a  ACOD  fue similar  en  los  2  grupos.  Entre  los  naïve,  los pacientes  que
iniciaban  rivaroxabán  (80,1%)  mostraron  mayor  adherencia  en  la  implementación  (MPR  > 80%),
mientras que  los  que  iniciaban  dabigatrán  fueron  menos  adherentes  (47,8%).
Conclusiones:  Acenocumarol  fue  el  anticoagulante  más  prescrito.  Los  pacientes  no naïve
mostraron  mejor  persistencia  al  tratamiento  que  los naïve.  Rivaroxabán  mostró  mayores  tasas
de adherencia  que  apixabán  y  dabigatrán,  las  menores.
© 2020  Los  Autores.  Publicado  por  Elsevier  España,  S.L.U.  Este  es  un  art́ıculo  Open  Access  bajo
la licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Direct  oral  anticoagulants  (DOAC) have  been  authorised  by
the  European  Medicines  Agency  for  stroke  prevention  and
systemic  embolism  in adult  patients  with  non-valvular  atrial
fibrillation  (NVAF)  during  the  last  years  (in  Spain  the  launch
date  was  2011 for  dabigatran,  2012  for  rivaroxaban,  2013  for
apixaban  and  2016  for  edoxaban).  Their  efficacy  and  safety
have  been  demonstrated  in  their  respective  pivotal  clinical
trials.1--4
The  level  of utilisation  of  the  different  DOAC  in stroke
prevention  in NVAF  has  shown  to  be  different  among
countries,  and several  cohort  studies  have  shown  dissimi-
lar  results  on  effectiveness  and  safety of these  drugs.5--12
Adequate  levels  of  adherence  and  persistence  to  anticoag-
ulant  treatment  have  shown  to  decrease  the  occurrence  of
embolic  events,13--16 so  other  studies  have  assessed  adher-
ence  and  persistence  to  oral  anticoagulants  (OAC),  also
showing  different  results  among  them.17--23 Adherence  has
been  defined  as  the  extent  to  which  the patient  conforms  to
the  medication  use  recommendations  specified  by the  pre-
scriber  (frequency  of administration,  dosage,  etc.),  and  it
is  divided  in three  phases:  initiation,  implementation  and
persistence.24 Initiation  can  be estimated  by  the  prescrip-
tions  actually  dispensed,  implementation  can be measured
by  medication  possession  ratio  (MPR),  and  persistence  is
defined  as  the continuation  of  the treatment  over time.25
Despite  the  introduction  of  DOAC  for  NVAF  management,
vitamin  K  antagonists  (VKA)  are still  the first  therapeu-
tic  option  for  stroke  prevention  in Spain,  according  to  the
Agencia  Española de Medicamentos  y  Productos  Sanitarios
(AEMPS).26
Please  cite  this  article  in press  as:  Giner-Soriano  M,  et al. The  use  and adherence  of oral  anticoagu-
lants  in  Primary  Health  Care  in Catalunya,  Spain:  A real-world  data  cohort  study.  Aten  Primaria.  2020.
https://doi.org/10.1016/j.aprim.2020.05.016
ARTICLE IN PRESS
+Model
APRIM-1909; No.  of Pages 10
Use  and  adherence  of oral  anticoagulants  in Primary  Health  Care  3
We  have  recently  described  apixaban  patients’  charac-
teristics  according  to  demographics,  comorbidity,  risk  of
thromboembolic  events  and  comedications  in a  paper.27
The  aim  of  the present  work  was  to  describe the  char-
acteristics  for  all  patients  initiating  any  oral  anticoagulant
drug  (DOAC  and VKA)  for  stroke  prevention  in NVAF  and to
estimate  adherence  during  the implementation  phase  and
persistence  to  DOAC  treatment.
Material and methods
This  is  an  observational  population-based  cohort  study  of
adult  patients  receiving  DOAC  and  VKA for stroke  prevention
in  NVAF,  identified  in the primary  healthcare  (PHC)  database
SIDIAP  (Information  System  for  Research  in Primary  Care)28
in  Catalonia,  Spain.  The  study  cohort  included  all  individ-
uals  diagnosed  with  NVAF  who  had a new  prescription  for
apixaban,  dabigatran,  rivaroxaban  or  VKA (acenocoumarol
or  warfarin)  from  August  2013  until  December  2015.  We
excluded  from  the study  those  patients  with  a  regis-
tered  diagnosis  of  valvular  heart  disease,  including  patients
with  mitral  prosthetic  valves.  All patients  enrolled  were
subdivided  in  four groups  according  to the treatment  initi-
ated:  apixaban,  dabigatran,  rivaroxaban  and VKA.  Patients
were  considered  naive  if they  did  not  have  prior  prescrip-
tion  of  any  OAC during  12  months  before  index  date,  or
non-naive  if  they  had  been previously  treated  during  the
previous  12  months  with  a different  OAC  from  the  OAC
that  caused  the entrance  to  the  study  cohort.  Patients
were  followed-up  until  the  discontinuation  of  anticoagulant
treatment.
The  data  source was  SIDIAP,28 which  currently  collects
anonymized  information  from  279 primary  health  care cen-
tres  managed  by  the  Catalan  health  institute  (ICS), which
covers  more  than  5.8  million  patients  (approximately  80%  of
the  Catalonia  population,  or  more  than  10%  of  the  Spanish
population).  The  information  in SIDIAP  is  generated  from  dif-
ferent  data  sources:  (1)  ECAPTM (electronic  health  records
in  PHC);  which  includes  information  since  2006  on  sociode-
mographic  characteristics,  health conditions  registered  as
ICD-10  codes,29 General  Practitioners’  prescriptions,  clini-
cal  parameters  and  toxic  habits.  (2)  Laboratory  data.  (3)
Pharmacy  invoice  data  available  since  2005:  information  on
all  pharmaceutical  products  dispensed  by community  phar-
macies  with  ICS prescriptions,  by  ATC codes.30
We  first  described  demographics,  comorbidity,  risk  of
thromboembolic  events  and comedications  of  all  patients
with  a  new  prescription  of OAC,  and  secondly,  we  described
medication  adherence  during implementation  and persis-
tence  to  anticoagulant  treatment  for  those  patients  whose
dispensing  data  were  available  and had at least one year
of  follow-up  in SIDIAP  database,  during  the period  between
August  2013  and  December  2014  in order  to  analyse  data  of
at  least  one  year  after initiation.
To  calculate  adherence  during  implementation  and
persistence  phases  we  only  took  into  account  those  patients
who  were  adherent  during initiation,  meaning  those  who
had  OAC  prescribed  and  dispensed.  Persistence  was  defined
as  no  discontinuation  of  treatment.  Discontinuation  rates  of
OAC  were  defined  by  lack  of  subsequent  dispensing  of the
index  drugs  within  2  months  after  last  supply  day  of  the last
dispensing  and were  analysed  by  calculating  the cumulative
percentage  of  discontinuation  (treatment  withdrawal  or
switch)  rate.
Therapeutic  adherence  during the implementation  phase
was  estimated  by  MPR,  which  is  the ratio  between  the  days
of  treatment  covered  by  the  medication  dispensed  and  the
total  number  of  days  between  the index  date  and  the last
dispensing,  and it was  measured  in persistent  patients  (those
with  at  least  one  year  of no  discontinuation).  Values  of  MPR
above  80%  were considered  as good  adherence  during  imple-
mentation.  The  package  size  has been  used  to  estimate  days
of  supply  for  DOACs (rivaroxaban  once  daily, dabigatran  and
apixaban  twice  daily)  as  the WHO  method  estimation  using
defined  daily  dose  does  not  separate  between  standard  and
low dose.30 Adherence  of  VKA treatment  cannot  be  properly
estimated  with  the  same  method,  as  doses  are  not  the same
for  every  day  of  the week,  they  change  after  INR  alterations
and,  moreover,  warfarin  and  acenocoumarol  pharmaceuti-
cal  products  in Spain  are available  at different  doses  and
contain  different  numbers  of  tablets.  Thus,  adherence  data
in  this paper  are  only  described  for  DOAC.
Statistical  analysis
Sociodemographic  characteristics  for  the four  groups  at
the  start  date  are provided:  (1)  for  all  variables,  num-
ber  and  percentage  of  missing  data;  (2)  for  categorical
variables  (sex,  toxic  habits  and  MEDEA  index31), num-
ber  and  percentage  for  each category;  (3)  for continuous
variables  (age,  body  mass  index),  mean  and standard  devi-
ation  (SD).  We  report  the total  number  of  patients  with
at  least  one  disease  and  the  number  and  percentage  of
patients  with  each  specific condition  for  all  groups  (apix-
aban,  dabigatran,  rivaroxaban  and VKA).  Concurrent  use  of
medications  at  the start date  was  quantified  by  the num-
ber  and  percentage  of  users.  Risk  of  stroke  and  major
haemorrhage  event  were  assessed  at the  start date with
CHA2DS2VASc
32 and  HAS-BLED.33 For each score,  number  and
percentage  of  each  category  for  the five  drugs groups  are
described.
Monthly  discontinuation  rates for  all  anticoagulant  during
the first  year  of treatment  were  also  calculated  in order  to
estimate  the persistence.  We  conducted  survival  analyses
of  the time  from  the index  date  to  the discontinuation  date
using survival  curves  drawn  using  the  Kaplan--Meier  method.
Censoring  was  considered  at  end  of  follow-up,  death  or  date
of  treatment  discontinuation.  For  each  DOAC  group,  number
and percentage  of  users  with  good  adherence  and summary
statistics  for  MPR  were  estimated.
Analysis  was  conducted  using SAS  software,  version  9.4
(SAS  Institute).  Detailed  methodology  for  summary  and
statistical  analyses  of  data  collected  in this  study  are  doc-
umented  in  the Statistical  Analysis  Plan,  which  is  dated,
filed  and  maintained  by  the sponsor  and can  be accessed
at  request  to  the  corresponding  author.
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Figure  1  Flowchart  of  patients  included  in the  study.  NVAF:  non-valvular  atrial  fibrillation,  VKA:  vitamin  K  antagonists.
Results
We  analysed  51,690  NVAF  patients  with  a new  OAC  pres-
cription  during  the study  period;  47,197  (91.3%)  were  OAC
naive  patients  and  4493  (8.7%)  were  non-naive,  and out  of
the  overall  number  of  patients,  16,637  (32.2%)  received  a
DOAC  prescription  and 35,053  (67.8%),  VKA  (Fig.  1, Table  1).
Demographics,  risk  of  stroke  and  haemorrhage,  comorbidi-
ties  and  comedications  are described  in Table  1.  Patients
initiating  anticoagulants  had  a mean  age  of  72.8  years  (SD
12.3),  49.4%%  of them  were  women  and  83.9%  of  patients
had  a  CHA2DS2VASc  score  ≥2.  The  youngest  patients  were
those  initiating  warfarin  (70.5  years)  and the oldest,  those
with  acenocoumarol  (73.5).  There  was  a higher  proportion  of
patients  prescribed  with  apixaban  with  a CHA2DS2VASc  score
≥2 than  for  the rest  of  the drugs  (86.1%)  and  the highest
haemorrhagic  risk  was  for acenocoumarol-treated  patients
(40.6%  with  HAS-BLED  ≥3  as  compared  to  23.1--35.0%
patients  with  HAS-BLED  ≥3  in  patients  receiving  other  OAC).
The  most  frequent  comorbidities  were  hypertension  (68%),
diabetes  (31.7%)  and  cancer  (25.6%),  and  the most fre-
quent  comedications  were proton  pump  inhibitors  (60.4%),
agents  acting  on  the  renin--angiotensin  system  (55.9%) and
statins  (42.4%).  Dispensing  data  were  available  for  41,146
patients  (79.6%)  of  those  patients;  8155  (19.9%)  patients
initiated  DOAC  treatment  and  32,991  (80.1%)  initiated
VKA  (Fig.  1).
Adherence  at implementation  and  persistence  were
assessed  through  dispensing  data  for  patients  who  initiated
anticoagulant  treatment  with  OAC  between  August  2013
and  December  2014  (n = 22,075),  being  only 1.9%  of them
(n  = 418)  non-naive  patients.  Of  the 22,075  patients,  3796
(17.2%)  received  DOAC;  3425  (n  =  15.8%)  of  them  were  naive
and  371  (88.7%)  were  anticoagulant-experienced  patients
(Table  2).
During  the first  month  of  treatment,  all DOAC-naive
patients  presented  high  discontinuation  rates,  being the
discontinuation  rates  higher  for  apixaban  (33.1%)  than
for  rivaroxaban  (30.6%)  and  for  dabigatran  (24.2%).
Discontinuation  rates in naive  patients  after  one  year  of
treatment  were  similar  between  the  three  DOAC,  with
approximately  60%  of  patients  stopping  treatment.  In  all
the naive  patients  the  persistence  at  one year was  less  than
50%  except  for  the  acenocoumarol  naive  patients  in whom  it
was  of  56.8%.  Persistence  was  higher  in  non-naive  patients
with  an observed  persistence  of  more  than  50%  at one  year,
being  higher  for  warfarin  non-naive  patients  (77.1%)  than
for  DOAC,  where  the maximum  persistence  was  observed  for
apixaban  patients  (66.1%)  and  the minimum  for  the dabiga-
tran  (48.5%)  patients.
For  the DOAC  naive  patients  with  at least one  year  of
follow-up  (n =  1299,  37.9%,  Table  3),  the  highest  adherence
at implementation  was  for  rivaroxaban  (80.1%),  followed
by  apixaban  (61.3%)  and  dabigatran  (47.8%).  For DOAC
non-naive,  225 (60.6%)  patients  did  not  discontinue  DOAC
treatment  during  the  first  year  and  among  them,  the  largest
proportion  of  patients  with  good  adherence  was  for  rivaroxa-
ban  (81.7%)  and  the  lowest  for dabigatran  (34.0%).  Although
the  measure  of  persistence  for  VKA should  be different  to  the
measure  for  DOAC,  in Fig.  2  we  show data  for  both groups  of
anticoagulants  in  order  to  compare  them.  This  figure  shows
Kaplan--Meier  curves  for treatment  discontinuation  of  DOAC
and  VKA  in naive  patients;  there  were high  DOAC  discon-
tinuation  rates  at treatment  start and, over  time  apixaban
showed  lower  discontinuation  rates.
Discussion
We  included  51,690  new  users of  OAC  in this population-
based  cohort  study,  41,146  of them had dispensing  data
available  in SIDIAP  (79.6%).  Approximately  80%  of  the
patients  initiated  VKA  rather  than  DOAC,  pointing  out that
VKA are still  the first  therapeutic  option  for  anticoagulation
in NVAF  in our  setting,  as  recommended  by  AEMPS.26 Most
patients  (83.9%) had CHA2DS2VASc  score  ≥2,  which is  the
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Table  1 Baseline  characteristics  of  patients  with  new  prescriptions  of  anticoagulants.
N, % Total
(n = 51,690)
Apixaban
(n =  6135)
Dabigatran
(n = 3808)
Rivaroxaban
(n  = 6694)
Acenocoumarol
(n = 32,404)
Warfarin
(n = 2649)
Naive patients 47,197 (91.3%) 4712 (76.8%) 2855 (75.0%) 5132 (76.7%) 32,212 (99.4%) 2286 (86.3%)
Non-naive  patients 4493 (8.7%) 1423 (23.2%) 953 (25.0%) 1562 (23.3%) 192 (0.6%) 363 (13.7%)
Female  25,559 (49.4%) 3412 (55.6%) 1878 (49.3%) 3460 (51.7%) 15,625 (48.2%) 1184 (44.7%)
Mean  age, years (SD) 72.8 (12.3) 73.2 (11.0) 71.6 (12.0) 71.0 (12.9) 73.5 (12.3) 70.5 (13.5)
≥80  years-old 17,200 (33.3%) 1879 (30.6%) 1065 (28.0%) 1809 (27.0%) 11,737 (36.2%) 710 (26.8%)
Smoking  habit 11,701 (22.6%) 1313 (21.4%) 826 (21.7%) 1483 (22.2%) 7302 (22.5%) 777 (29.3%)
Glomerular  filtration rate (mL/min/1.73 m2)
Missing  GFR 9788 (18.9%) 1249 (20.4%) 839 (22.0%) 1636 (24.4%) 5561 (17.2%) 503 (19.0%)
GFR  ≥ 60 30,687 (59.4%) 3605 (58.8%) 2363 (62.1%) 3908 (58.4%) 19,248 (59.4%) 1563 (59.0%)
GFR  30--45 10,248 (19.8%) 1198 (19.5%) 577 (15.1%) 1088 (16.3%) 6867 (21.1%) 518 (19.6%)
GFR  <  30 967 (1.9%) 83 (1.4%) 29 (0.8%) 62 (0.9%) 728 (2.2%) 65 (2.5%)
BMI  groups (kg/m2)
Missing 12,408 (24.0%) 1685 (27.5%) 1138 (29.9%) 2057 (30.7%) 6932 (21.4%) 596 (22.5%)
18.5--25  (normal) 6701 (13.0%) 676 (11.0%) 416 (10.9%) 735 (11.0%) 4501 (13.9%) 373 (14.1%)
<18.5  (underweight) 201 (0.4%) 18 (0.3%) 18 (0.5%) 16 (0.2%) 141 (0.4%) 8 (0.3%)
25--30  (overweight) 15,507 (30.0%) 1722 (28.1%) 1041 (27.3%) 1771 (26.5%) 10,142 (31.3%) 831 (31.4%)
>30  (obese) 16,873 (32.6%) 2034 (33.2%) 1195 (31.4%) 2115 (31.6%) 10,688 (33.0%) 841 (31.7%)
CHA2DS2VASc
0  or 1  (woman) 4902 (9.5%) 480 (7.8%) 476 (12.5%) 887 (13.3%) 2738 (8.4%) 321 (12.1%)
1  3398 (6.6%) 375 (6.1%) 280 (7.4%) 500 (7.5%) 2040 (6.3%) 203 (7.7%)
≥2 43,390  (83.9%) 5280 (86.1%) 3052 (80.1%) 5307 (79.2%) 27,626 (85.3%) 2125 (80.2%)
HAS-BLED
0  4166 (8.1%) 540 (8.8%) 509 (13.4%) 903 (13.5%) 1918 (5.9%) 296 (11.2%)
1--2  29,391 (56.9%) 3927 (64.0%) 2405 (63.2%) 4243 (63.4%) 17,322 (53.5%) 1494 (56.4%)
≥3  18,133 (35.0%) 1668 (27.2%) 894  (23.4%) 1548 (23.1%) 13,164 (40.6%) 859 (32.4%)
Comorbidities
Heart  failure 6133 (11.9%) 866 (14.1%) 439 (11.5%) 783 (11.7%) 3656 (11.3%) 389 (14.7%)
Peripheral artery disease 2764 (5.3%) 323 (5.3%) 154 (4.0%) 294 (4.4%) 1801 (5.6%) 192 (7.2%)
Ischaemic  heart disease 7406 (14.3%) 802 (13.1%) 472 (12.4%) 856 (12.8%) 4795 (14.8%) 481 (18.2%)
Acute  myocardial infarction 2460 (4.8%) 246 (4.0%) 130  (3.4%) 263 (3.9%) 1638 (5.1%) 183 (6.9%)
Hypertension  35,144 (68.0%) 4295 (70.0%) 2428 (63.8%) 4364 (65.2%) 22,305 (68.8%) 1752 (66.1%)
Diabetes  mellitus 16,403 (31.7%) 1986 (32.4%) 1146 (30.1%) 1981 (29.6%) 10,425 (32.2%) 865 (32.7%)
Cerebrovascular disease 6248 (12.1%) 891 (14.5%) 523 (13.7%) 731 (10.9%) 3725 (11.5%) 378 (14.3%)
Cancer  13,211 (25.6%) 1606 (26.2%) 940 (24.7%) 1698 (25.4%) 8249 (25.5%) 718 (27.1%)
Comedications
Proton  pump inhibitors 31,200 (60.4%) 4308 (70.2%) 2346 (61.6%) 4357 (65.1%) 18,489 (57.1%) 1700 (64.2%)
Drugs  used in diabetes 11,684 (22.6%) 1404 (22.9%) 805  (21.1%) 1348 (20.1%) 7494 (23.1%) 633 (23.9%)
Platelet  aggregation inhibitors 9105 (17.6%) 985 (16.1%) 518 (13.6%) 997 (14.9%) 6082 (18.8%) 523 (19.7%)
Diuretics  19,051 (36.9%) 2131 (34.7%) 1211 (31.8%) 2223 (33.2%) 12,281 (37.9%) 1205 (45.5%)
Beta  blocking agents 21,113 (40.8%) 2075 (33.8%) 1576 (41.4%) 2374 (35.5%) 13,867 (42.8%) 1221 (46.1%)
Calcium  channel blockers 10,389 (20.1%) 1197 (19.5%) 735  (19.3%) 1266 (18.9%) 6669 (20.6%) 522 (19.7%)
Agents  acting on the renin--angiotensin system 28,880 (55.9%) 3469 (56.5%) 2070 (54.4%) 3575 (53.4%) 18,377 (56.7%) 1389 (52.4%)
Statins  21,922 (42.4%) 2657 (43.3%) 1522 (40.0%) 2722 (40.7%) 13,714 (42.3%) 1307 (49.3%)
Non-steroidal anti-inflammatory drugs 6429 (12.4%) 1805 (29.4%) 623 (16.4%) 1594 (23.8%) 2239 (6.9%) 168 (6.3%)
SD: standard deviation, GFR: glomerular filtration rate, BMI: body mass index.
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Table  2  Descriptive  of  adherence  and  discontinuation  rates  of  anticoagulants  in naive  and  non-naive  patients.
First  year  discontinuation,  n  (%)
Naive  patients  Total  (n  =  21,657)  Apixaban  (n  =  958)  Dabigatran  (n  = 1152)  Rivaroxaban  (n  =  1315)  Acenocumarol  (n  =  16,953)  Warfarin  (n  =  1279)
No  discontinuation  11,502  (53.1%)  375  (39.1%)  425 (36.9%)  499  (37.9%)  9634  (56.8%)  569  (44.5%)
Discontinuation at 1st  month  1854  (8.6%)  317  (33.1%)  279 (24.2%)  402  (30.6%)  840  (5.0%)  16  (1.3%)
Discontinuations at 6th  month  6420  (29.6%)  472  (49.3%)  564 (49.0%)  679  (51.6%)  3648  (21.5%)  457  (35.7%)
Discontinuations at 1st  year  10,155  (46.9%)  583  (60.9%)  727  (63.1%)  816 (62.1%)  6719  (39.6%)  710  (55.5%)
Non-naive patients  Total  (n  =  418)  Apixaban  (n  = 124)  Dabigatran  (n  =  103)  Rivaroxaban  (n  =  144)  Acenocumarol  (n  = 12)  Warfarin  (n  =  35)
No  discontinuation  258 (61.7%)  82  (66.1%)  50  (48.5%)  93  (64.6%)  6  (50.0%)  27  (77.1%)
Discontinuation at 1st  month  23  (5.5%)  2 (1.6%)  13  (12.6%)  7 (4.9%)  1  (8.3%)  0  (0.0%)
Discontinuations at 6th  month  99  (23.7%)  19  (15.3%)  39  (37.9%)  33  (22.9%)  5  (41.7%)  3 (8.6%)
Discontinuations at 1st  year  160 (38.3%)  42  (33.9%)  53  (51.5%)  51  (35.4%)  6  (50.0%)  8 (22.9%)
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Table  3  Descriptive  statistics  of  adherence  rates  of  direct  oral  anticoagulants  in  naive  and  non-naive  patients.
Medication  possession  ratio,  n  (%)
Naive  patients  (n  =  3425)  Apixaban  (n  = 958)  Dabigatran  (n =  1152)  Rivaroxaban  (n =  1315)
Less  than  one  year  of  follow-up  583  (60.9%)  727  (63.1%)  816  (62.1%)
N with  at  least  1 year  of  follow-up  375  (39.1%)  425  (36.9%)  499  (37.9%)
Non-adherence  (<80%)  145  (38.7%)  222  (52.2%)  139  (27.9%)
Good adherence  (≥80%)  230  (61.3%)  203  (47.8%)  360  (80.1%)
MPR, median  (IQR)  90.4  (53.4--98.6)  79.5  (72.3--95.3)  92.6  (77.1--99.7)
Non-naive patients  (n = 371)  Apixaban  (n  = 124)  Dabigatran  (n  =  103)  Rivaroxaban  (n  =  144)
Less  than  one  year  of  follow-up  42  (33.9%)  53  (51.5%)  51  (35.4%)
N with  at  least  1 year  of  follow-up  82  (66.1%)  50  (48.5%)  93  (64.6%)
Non-adherence  (< 80%)  27  (32.9%)  33  (66.0%)  17  (18.3%)
Good adherence  (≥80%)  55  (67.1%)  17  (34.0%)  76  (81.7%)
MPR, median  (IQR)  94.5  (53.4--98.6)  75.1  (71.6--94.7)  99.7  (84.4--99.7)
MPR: medication possession ratio, IQR: interquartile range.
criterion  to  anticoagulate  in NVAF  patients  according  to
guidelines.34,35 Patients  with  highest  risks of  stroke  were
those  in  the  groups  of acenocoumarol  and  apixaban,  as
shown  in  previous  studies  for  the  other  VKA,  warfarin.14,22,36
Therapeutic  adherences  at  implementation  and persis-
tence  to  OAC  were  assessed  in those  patients  who  were
adherent  at initiation  and  started  anticoagulation  treat-
ment  before  2015.  Only  one  third  of  naive  patients  received
Naive
APIXABAN
DABIGATRAN
RIVAROXABAN
ACENOCUMAROL
WARFARIN
1.0
0.8
0.6
0.4
0.2
0.0
0.0 0.5 1.0 1.5 2.0
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2.5 3.0
Figure  2  Discontinuation  of direct  oral  anticoagulants  and vitamin  K antagonists  in  naive  patients.
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DOAC  treatment  during  at  least  one year  of  follow-up,  for
VKA  the  proportion  was  higher.  Between  them,  rivaroxaban
group  showed  the highest  percentage  of patients  with  good
adherence  at  implementation  (MPR  ≥80)  and  dabigatran  the
lowest.  Similar  results  were  also  found  by  Forslund  et al.22
or  by  Beyer-Westendorf  et  al.23 although  this last  study  only
analysed  rivaroxaban  and  dabigatran.  On  the opposite,  other
studies  found  higher  MPR  in  apixaban-treated  patients.14,37
Regarding  persistence  to DOAC  in naive  patients,  apix-
aban  showed  higher  discontinuation  rates  during  the first
month  of treatment  but  at one  year, all  DOAC  showed  sim-
ilar  rates.  Several  studies  analysed  discontinuation  rates at
different  times  during follow-up.  After  one  year,  apixaban
users  were  more  persistent  than  other  DOAC  and  VKA  users
in  the  studies  conducted  by  Forslund  et  al.22 and  Johnson
et  al.21
Other  studies  which  analysed  persistence  in  naive
patients  only  included  dabigatran  and  rivaroxaban.  Rivarox-
aban  presented  better  persistence  than dabigatran  and
VKA.23,38
Manzoor  et  al.37 or  Martínez  et  al.39 studied  all  DOAC
together  as  a group.  The  first  one  showed higher  levels  of
persistence  to  DOAC  in anticoagulant-experienced  patients
over  time.  Martínez  et  al. found  higher  levels  of  persistence
in  DOAC  versus  VKA  users,  which  slightly  decreased  during
the  first  year  of  follow-up  (from  94.7%  of persistents  to  DOAC
at  3 months  to  72.9%  at 12  months).
For  anticoagulant-experienced  patients  with  more  than
one  year  of  follow-up  in our  study,  again  rivaroxaban  showed
the  largest  proportion  of  patients  with  good adherence  dur-
ing  implementation.  Only  Manzoor  et  al.37 analysed  MPR
in  non-naive  patients  and  apixaban  showed  higher  MPR  in
apixaban  at 6  months  and dabigatran  at 9  months.  Dis-
continuation  rates  in our  non-naive  patients  were  much
lower  than  for  the  naive  ones;  during  the first  month  since
treatment  initiation  1.6%  apixaban,  4.9%  rivaroxaban  and
12.6%  dabigatran  patients  discontinued  the treatment,  and
after  one  year  rivaroxaban  users  showed  lower  persistence
rates  (48.5%)  than  apixaban  and dabigatran  (66.1%  and
64.6%,  respectively).  Manzoor  et  al.37 compared  persistence
between  naive  and  non-naive  patients  receiving  DOAC  and
the  last  ones  showed  higher  levels  of  persistence.  Johnson
et  al.21 described  similar  discontinuation  rates  than  for  naive
patients  and  at  the end-of  follow-up  patients  prescribed
apixaban  showed  improved  persistence  over  dabigatran,
rivaroxaban  and  VKA.
The  differences  in treatment  persistence  between  naive
and  anticoagulant-experienced  patients  in our  study  could
be  motivated  by  a  better  knowledge  of  the  anticoagulation
importance  of  these  patients  who  previously  received  mainly
VKA,  and  they  were  used  to  attend  monthly  to  PHC cen-
tres  for  INR  determination  and  had  optimal  levels  of drug
adherence.
Suboptimal  adherence  to  anticoagulant  therapy  places
patients  with  AF at  risk  for  stroke  or  bleeding  complications.
Our  study  concludes  as  most  observational  studies,  that  the
guidelines  recommendations  regarding  anticoagulant  ther-
apy  are  not  routinely  followed  in clinical  practice,  and
adherence  is  substantially  lower  than  in clinical  trials.3,40
Some  specific  limitations  in our  database  are  the  lack
of  association  between  GP’s prescriptions  and dispensing
associated  with  these  prescriptions.  This  study  has  missing
data  from  pharmacy  claims  and  for  some  variables  as  it is
common  in observational  studies  using electronic  databases
(information  bias).  The  strengths  of our  study  are  repre-
sentativeness  for  the  general  population,  with  a database
that  covers  almost  the  80%  of  the  Catalonian  population,
with  complete  sociodemographic  and  health records,  long
follow-up,  and  real clinical  practice  data.
What is known on  the  topic
•  The  level  of  utilisation  of  the different  DOAC  in
stroke  prevention  in NVAF  has  shown  to  be  differ-
ent  among  countries,  and several  cohort  studies  have
shown  dissimilar  results  on  adherence,  effectiveness
and safety  of  these  drugs.
•  Adequate  levels  of  adherence  and  persistence  to
anticoagulant  treatment  have  shown  to  decrease  the
occurrence  of  embolic  events.
What this  study contributes
•  Vitamin  K  antagonists  are  still  the  first  option  to  anti-
coagulate  NVAF  patients  in our  setting.
•  We  measured  adherence  and  persistence  for  DOAC
patients.  Adherence  was  higher  for  rivaroxaban,  fol-
lowed  by  apixaban  and  dabigatran.
•  Persistence  to  DOAC  was  low in  our  setting,  which
may  result  in  higher  risk  of  thromboembolic  events.
Discontinuation  rates were  higher  in naive  than  in
non-naive  patients.  This  may  be caused  by  better
knowledge  of  the  importance  of  treatment  adher-
ence  in patients  who  have  previously  received  VKA,
which  need  a more  strict management.
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